The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article

Abstract

Janus kinase (JAK) inhibitors have emerged as a groundbreaking option in dermatologic therapy, offering a more precise approach to manage inflammatory and autoimmune skin diseases. This narrative review explores the use of JAK inhibitors in three key conditions: atopic dermatitis, alopecia areata, and vitiligo. These disorders share a common underlying mechanism involving disruption of the JAK-STAT signaling pathway, which contributes to abnormal immune responses. A growing body of clinical research highlights the effectiveness of both topical and oral JAK inhibitors in managing symptoms across these conditions. For instance, ruxolitinib cream and oral agents such as abrocitinib, baricitinib, and upadacitinib have shown strong anti-inflammatory effects and relief of itching in atopic dermatitis. In the treatment of alopecia areata, medications like baricitinib, ritlecitinib, and the recently approved deuruxolitinib have brought renewed optimism for individuals with more severe forms of the disease. Meanwhile, topical ruxolitinib has shown promise in restoring pigment, particularly on facial areas affected by vitiligo. Although these therapies are generally well-tolerated, potential risks such as infections and cardiovascular concerns necessitate ongoing safety monitoring. Overall, this review brings together the latest evidence on the use of JAK inhibitors in dermatology, highlighting their clinical impact and underscoring the need for continued research to optimize long-term safety and patient selection.